Dishman Carbogen Amcis Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cu39v2fxi5zn6vxi1x93by9m.pdf

Key Takeaways


Carbogen Amcis: The Quarter's Engine

Pascal Villemagne: "Our current development project pipeline is also extremely healthy because we are above CHF 10 crore of development project within Carbogen Amcis. We are reaching CHF 11.4 crore now, which represents more than a year of work for all the value at Carbogen Amcis."

One-Time Costs That Distorted the Quarter


India: The Margin Recovery Story

Harshil Dalal: "We do expect that the next year, we should have the India facilities do revenue, which is at least 15% to 20% more than what it would do by the end of this financial year. And this is obviously on a conservative basis."

France Facility: Live and Booking Orders

Pascal Villemagne: "Our business plan has been clear. Next year, we want to reach at least CHF1.5 crore revenue for that facility. Top line and when that facility is going to run with two-shift system, we plan to reach EUR3 crore for that unit."

European Cost Pressures and the Pass-Through Lag


Biotech Funding: Comfortable for Now, Unclear Beyond

Pascal Villemagne: "As far as time being, we haven't suffered from that. We still have some pipeline of products, and we are quite comfortable for the next fiscal year. Beyond that, it's obviously very difficult to predict."

Guidance & Commitments

CommitmentSpecificsTimeline
EDQM normalcy at BavlaBavla should commence normal operations; reinspection triggered and expected per regulatory timelinesQ1 FY24
India revenue growthIndia facilities (Bavla + Naroda) to deliver revenue at least 15–20% above FY23 exit, on a conservative basisFY24
Group margin expansionMargins to increase significantly as India operations come back on track and European cost pass-through takes effectStarting FY24
French facility first revenueFirst order booked, to be manufactured by June; FY24 target of at least CHF 1.5 cr revenueJune 2023 / FY24
Swiss ADC expansion contributionBubendorf ADC extension for Japanese customer to start contributingH1 FY24 (second quarter)
FY24 revenue growthRevenue expected to grow 12–14%FY24
FY24 EBITDA growthEBITDA growth expected at a much higher rate than revenue growth, aided by India EDQM base-effect normalizationFY24
Maintenance CAPEX~₹300-odd crores per year; ~₹500-odd crores total over 2–2.5 years including India upgradesNext 2–2.5 years

Key Metrics

MetricQ3 FY23
Consolidated revenue₹640 cr, best quarter in the last 10 quarters
9M FY23 consolidated revenue₹1,794 cr
Consolidated EBITDA₹115 cr, 18% margin
9M FY23 consolidated EBITDA₹287.5 cr, ~16% margin
Profit before tax₹45.6 cr, compared to ₹38.4 cr in Q3 FY22
9M FY23 profit before tax₹33 cr
Carbogen Amcis segment revenue₹462 cr, +10% YoY for Q3; +16% for 9M
Carbogen Amcis segment EBITDA margin~22% for Q3, compared to 20% in Q3 FY22; ~19% for 9M vs 20% in 9M FY22
India NCE API revenue₹46 cr, compared to ₹39.6 cr in Q3 FY22
India Quats and Generics revenue~₹49 cr, compared to ₹46.5 cr in Q3 FY22
India Quats and Generics EBITDA margin~7.3%
Dutch business EBITDA margin~17%
FY24 revenue growth expectation12% to 14%; EBITDA growth expected to be much higher
Carbogen Amcis development project pipelineCHF 11.4 cr, above CHF 10 cr
Provision for onerous contracts₹24 cr booked in Q3
Foreign exchange loss₹34 cr booked in Q3
Finance cost~₹22 cr, including forex loss of ~₹3.5 cr
Depreciation and amortization~₹50 cr, compared to ₹75 cr in Q3 FY22; goodwill amortization period extended from 15 to 22 years, reducing annual P&L charge by almost 50% from ₹89 cr
Energy cost~₹21 cr, compared to ~₹15 cr in Q3 FY22; 9M FY23 energy cost ₹66 cr, up almost 50% YoY
EDQM one-time expense₹7–7.5 cr in Q3, compared to ~₹12 cr in Q2
CAPEX guidance~₹300-odd cr per year for next 2 financial years, total ~₹500-odd cr over 2–2.5 years, mostly maintenance CAPEX
French facility FY24 revenue targetat least CHF 1.5 cr; full two-shift capacity target EUR 3 cr
Swiss wage inflation expectationaround 2.8% to 3% for FY24